Halozyme Therapeutics (NASDAQ:HALO) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

HALO has been the subject of several other reports. BMO Capital Markets increased their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Wednesday, September 27th. Barclays lowered shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and increased their price objective for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. Canaccord Genuity increased their price objective on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Deutsche Bank raised their price target on shares of Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a research report on Friday, September 15th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $18.13.

Halozyme Therapeutics (HALO) opened at $18.14 on Tuesday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 3.37 and a current ratio of 3.46. Halozyme Therapeutics has a 1 year low of $9.68 and a 1 year high of $19.37.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The business’s revenue for the quarter was up 100.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) earnings per share. equities analysts expect that Halozyme Therapeutics will post 0.15 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP raised its position in Halozyme Therapeutics by 161.0% during the 3rd quarter. Rubric Capital Management LP now owns 783,000 shares of the biopharmaceutical company’s stock worth $13,601,000 after buying an additional 483,000 shares during the last quarter. California Public Employees Retirement System raised its position in Halozyme Therapeutics by 1.6% during the 3rd quarter. California Public Employees Retirement System now owns 197,700 shares of the biopharmaceutical company’s stock worth $3,434,000 after buying an additional 3,200 shares during the last quarter. Allianz Asset Management GmbH raised its position in Halozyme Therapeutics by 9.9% during the 3rd quarter. Allianz Asset Management GmbH now owns 76,309 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 6,888 shares during the last quarter. Artisan Partners Limited Partnership raised its position in Halozyme Therapeutics by 43.8% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,435,886 shares of the biopharmaceutical company’s stock worth $24,941,000 after buying an additional 437,479 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Halozyme Therapeutics by 11.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 570,513 shares of the biopharmaceutical company’s stock worth $9,910,000 after buying an additional 58,707 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Halozyme Therapeutics (HALO) Rating Lowered to Hold at BidaskClub” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/07/halozyme-therapeutics-halo-rating-lowered-to-hold-at-bidaskclub.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.